EP Patent

EP3882249B1 — Deuterated derivatives of ruxolitinib

Assigned to Sun Pharmaceutical Industries Inc · Expires 2025-05-14 · 1y expired

What this patent protects

Patent listed against valbenazine-tosylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3882249B1
Jurisdiction
EP
Classification
Expires
2025-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Sun Pharmaceutical Industries Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.